Literature DB >> 12804048

Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.

Hazel Breitz1, Richard Wendt, Michael Stabin, Lionel Bouchet, Barry Wessels.   

Abstract

A study was undertaken to determine the maximum tolerated dose of (166)Ho-DOTMP that could be administered safely, without negatively impacting marrow re-engraftment, in patients with multiple myeloma treated with melphalan prior to transplant. Ho-166 DOTMP is a tetraphosphonate that localizes rapidly to bone surface. The Ho-166 physical half-life is 26.8 hr and the maximum beta energy is 1.8 MeV. Standard dosimetry models were adapted for radiation absorbed dose estimates using data obtained from whole body counting of the low abundance photons emitted by (166)Ho. Eighty-three patients received high dose (166)Ho-DOTMP followed by melphalan and transplant of peripheral blood stem cells. Twenty-five patients also received 8 Gy total body radiation (TBI). Dosages administered ranged from 460 to 4476 mCi (166)Ho-DOTMP. Marrow dose was derived using the assumption that all radioactivity not excreted by 20 hours was localized to the bone surfaces, and applying the Eckerman bone and marrow dose model to the calculated bone residence times. The dosimetry of the urinary bladder and kidneys was important because of the rapid excretion of the non-targeted radioactivity via the urinary pathway. The dynamic bladder model was used for bladder wall surface dose, and the ICRP 53 kinetic model was used to model kidney kinetics with an additional blood component included. Marrow doses ranged from 13 to 59 Gy and successful hematapoietic recovery occurred. Bladder doses ranged from 4.7 to 157 Gy. Hemorrhagic cystitis occurred in some patients who received more than 40 Gy to the bladder wall surface. Bladder irrigation was successful in protecting patients from bladder toxicity. Kidney doses ranged from 0.5-7.9 Gy. Kidney toxicity in the form of thrombotic microangiopathy with renal dysfunction was observed, with the severity being related to Ho-166-DOTMP radiation dose and probably the dose rate as well. In a future trial, kidney dosimetry will be assessed using early serial gamma camera imaging and modifications will be implemented to reduce renal toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804048     DOI: 10.1089/108497803765036391

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  11 in total

1.  Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.

Authors:  Mahdokht Vaez-Tehrani; Samaneh Zolghadri; Hassan Yousefnia; Hossein Afarideh
Journal:  Br J Radiol       Date:  2016-08-15       Impact factor: 3.039

Review 2.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

3.  A case of severe hemorrhagic cystitis caused by melphalan with successful bladder preservation by ligation of bilateral internal iliac arteries.

Authors:  Takumi Takeuchi; Masayoshi Zaitsu; Koji Mikami; Yuta Takeshima; Takashi Matsunaga; Naohiko Okamoto; Sadao Imao
Journal:  Case Rep Med       Date:  2010-06-14

4.  Development of (166)Ho-phytate Complex for Radiosynovectomy.

Authors:  Amir R Jalilian; Akbar Anvari; Ali Bahrami-Samani; Mohammad Mazidi; Mohammad Ghannadi-Maragheh
Journal:  Nucl Med Mol Imaging       Date:  2011-02-17

5.  Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.

Authors:  Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

6.  Development of (177)Lu-phytate Complex for Radiosynovectomy.

Authors:  Hassan Yousefnia; Amir Reza Jalilian; Ali Bahrami-Samani; Mohammad Mazidi; Mohammad Ghannadi Maragheh; Fereydoun Abbasi-Davani
Journal:  Iran J Basic Med Sci       Date:  2013-05       Impact factor: 2.699

7.  Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation.

Authors:  Samaneh Zolghadri; Hassan Yousefnia; Amir Reza Jalilian; Mohammad Ghannadi-Maragheh
Journal:  Asia Ocean J Nucl Med Biol       Date:  2015

8.  Preparation and evaluation of Lu-(177) phytate Complex for Radiosynovectomy.

Authors:  Hassan Yousefnia; Amir Reza Jalilian; Samaneh Zolghadri
Journal:  World J Nucl Med       Date:  2014-01

Review 9.  Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.

Authors:  Tiantian Li; Edwin C I Ao; Bieke Lambert; Boudewijn Brans; Stefaan Vandenberghe; Greta S P Mok
Journal:  Theranostics       Date:  2017-10-13       Impact factor: 11.556

Review 10.  The various therapeutic applications of the medical isotope holmium-166: a narrative review.

Authors:  Nienke J M Klaassen; Mark J Arntz; Alexandra Gil Arranja; Joey Roosen; J Frank W Nijsen
Journal:  EJNMMI Radiopharm Chem       Date:  2019-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.